HORIBA has entered into a strategic partnership with MEDCONN Diagnostics to expand its U.S. diagnostic laboratory portfolio. The MEDCONN MQ-3000 and MQ-8000 systems will be distributed in clinical laboratories across the U.S. this summer.

The MEDCONN MQ-3000 and MQ-8000 Glycated Hemoglobin Analyzers complement HORIBA’s existing diabetes testing portfolio by providing laboratories with additional flexibility and efficiency in managing testing workflows. Together, these systems support reliable, high-quality diagnostic performance while expanding access to solutions designed to meet the evolving needs of clinical laboratories. By enhancing its diabetes testing portfolio, HORIBA aims to help laboratories optimize efficiency, scalability, and diagnostic confidence.  

HORIBA is actively preparing for product commercialization to support a seamless introduction into clinical laboratory environments. 

Visit HORIBA for more information